The GLP-1 aftermath: what happens to the digital health companies that formed around them
A category defined by a single drug class is inherently fragile. The next act requires more than a coaching wrapper.
The initial thesis
The first wave of GLP-1-adjacent companies built patient-acquisition machines and coaching wrappers around a pharmacological breakthrough. The economics were exceptional — briefly.
The pressure now
Payer coverage tightening, employer skepticism, and pharma-direct offerings have compressed margins meaningfully. The pure coaching wrappers are struggling.
Who survives
The companies expanding into adjacent chronic care, building deeper clinical services, or acquiring at-risk provider relationships are positioning well for a durable second act.
The lesson
Building a company entirely around a drug class you do not control is a strategy with a shelf life. Plan for the pivot from day one.
